Table 4 Previous Reports of Immunohistochemically Detectable PSA Expression in Benign and Malignant Breast Lesions

Carder et al. 2005 [2]

11 MBC

Dako, ELY, Cambridgeshire, UK

1/11 (9%)

Focal intense staining

All cases PSAP negative (Dako)

Cheng et al. 2006 [3]

14 MBC

Dako, Glostrup, Denmark

0/14

All cases PSAP negative

Ilvan et al. 2004 [10]

109 FBC

Dako USA, monoclonal, prediluted

11/109 (10.1%)

All PSA positive cases ER+ PR+

Miller et al. 2001 [11]

75 (74 FBC, 1 MBC)

Dako M0750 1:320

7/75 (9%)

5/7 showed weak, focal positivity; MBC negative

Kidwai et al. 2003 [12]

26 MBC

Dako polyclonal 1:1800

6/26 (23%)

5 focally positive

1 diffuse

All PSAP negative

Narita et al. 2006 [13]

156 FBC

Dako polyclonal, ready to use

61/156 (39.1%)

Positive correlation with AR expression

Hall et al. 1998 [14]

72 cases

Dako, Carpinteria, CA

44/72 (61%)

Alanen et al. 1999 [15]

171 cases

Dakopatts, Glostrup, Denmark, polyclonal 1:1000

54/171 (31.6%)

Gatalica et al. 1999 [19]

18 gynecomastia, 8 MBC

Rabbit polyclonal, Ventana Medical Systems, Tucson AZ

5/18 cases of gynecomastia (27.8%)

0/8 MBC

Focal strong polyclonal PSA; 4/5 cases tested with monoclonal PSA and were negative

All cases PSAP (Ventana PASE/4LT) negative

Quraishi et al. 2007 [20]

30 (8 DCIS, 19 infiltrating ductal carcinoma, 3 metastatic breast carcinoma)

Polyclonal rabbit

0/30

Gupta 1999 [21]

2 MBC

Not reported

2/2 (100%)

Cell blocks positive; trace PSA positivity in resection specimens

Tanaka et al. 2002 [22]

78 FBC

Dako A/S Glostrup, Denmark, polyclonal 1:100

29/78 (32.7%)

6 cases strongly positive

This article

54 FBC

30 MBC

5 gynecomastia

Dako polyclonal 1:10,000

2/54 FBC

1/30 MBC

0/5 gynecomastia

All cases PSAP negative